---
layout: default
title: Panitumumab
parent: 僅模型預測 (L5)
nav_order: 331
evidence_level: L5
indication_count: 10
---

# Panitumumab
{: .fs-9 }

證據等級: **L5** | 預測適應症: **10** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Panitumumab: From Undocumented Original Indication to Drug-Induced Osteoporosis

## One-Sentence Summary

Panitumumab (DrugBank DB01269) currently has no recorded original indication or mechanism-of-action data in this evidence pack, and it holds no marketing authorisation in Denmark. The TxGNN model predicts a possible link to **Drug-Induced Osteoporosis**, but this prediction is currently supported by **0 clinical trials** and **0 publications**.

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Not available (data gap) |
| Predicted New Indication | Drug-induced osteoporosis |
| TxGNN Prediction Score | 99.13% |
| Evidence Level | L5 |
| Denmark Market Status | Not marketed |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Detailed mechanism-of-action data for Panitumumab is not available in this evidence pack (flagged as a High-severity data gap), and no original indication is currently on record. Panitumumab is known in the drug knowledge graph as an anti-EGFR monoclonal antibody, but without a documented original indication or MOA in this pack, no evidence-based link can be drawn between its known pharmacology and the proposed bone-metabolism pathway (RANKL/OPG, osteoclast activity) underlying drug-induced osteoporosis.

The model's own rationale for this candidate states explicitly that no direct mechanistic connection is established, and that the high TxGNN score (0.991) likely reflects an indirect association in the knowledge graph between the broader EGFR-inhibitor drug class and bone-density-related adverse-effect nodes, rather than Panitumumab-specific evidence.

Because both the original-indication and MOA fields are data gaps, and no clinical or literature evidence exists for this candidate, the biological plausibility of this prediction cannot currently be assessed and should be treated as a hypothesis generated purely from graph-level associations.

---

## Clinical Trial Evidence

Currently no related clinical trials registered.

---

## Literature Evidence

Currently no related literature available.

---

## Denmark Market Information

Panitumumab currently has no marketing authorisation registered in Denmark (0 authorisations on file).

---

## Safety Considerations

Please refer to the approved Summary of Product Characteristics (SmPC) for safety information.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
This candidate rests on Evidence Level L5 (model prediction only) — there are no clinical trials or publications, no documented mechanism of action, and no original indication on record to assess biological plausibility. In addition, a Blocking-severity data gap exists for Danish label warnings/contraindications, which independently prevents any safety pre-assessment.

**To proceed, the following is needed:**
- Panitumumab's original indication and confirmed mechanism of action (DrugBank/label lookup)
- Danish/EU Summary of Product Characteristics (SmPC) — warnings, contraindications, and drug interactions
- DrugBank therapeutic category data to determine cytotoxicity/oncology classification
- Any emerging clinical trial or literature evidence specific to drug-induced osteoporosis, diabetic retinopathy, or cataract-related candidates before further evaluation
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

